RESUMEN

Trichinosis is a serious parasitic zoonotic disease caused mainly by Trichinella spiralis. The used drugs for treatment of trichinosis showed limited bioavailability and high degree of resistance. Moreover, they have a very poor effect in treatment of encysted larvae. Therefore, there is a need for development of new agents which help in improving the bioavailability of the used drugs and enable them to reach different tissues. This study was designed to assess the use of chitosan nanoparticles (CSNPs) in conjugation with full and half dose albendazole (ABZ) in treatment of intestinal and muscular trichinosis. Albino mice (84 mice) were used to evaluate the efficacy of drugs and divided into seven groups; I: control, II: ABZ (50 mg/kg) treated, III: ABZ (25 mg/kg) treated, IV: ABZ (50 mg/kg) conjugated CSNPs treated, V: ABZ (25 mg/kg) conjugated CSNPs treated, VI: CS treated and VII: CSNPs treated. Parasitological and histopathological examinations were used to evaluate the therapeutic efficacy of the used drugs. Results showed significant reduction of adult Trichinella extracted from intestine of all ABZ treated groups either conjugated or not with the highest reduction rate in group IV followed by group V with percentage of reduction of 99.33% and 98.11%, respectively and marked improvement of histopathological examination. Also, results showed significant reduction of Trichinella larvae extracted from muscles of group IV, V and VII with the highest reduction rate in group IV with percentage of reduction of 100% in muscle larvae and marked improvement of histopathological examination. It was concluded that albendazole full dose conjugated chitosan nanoparticles can be a good candidate drug for treating both intestinal and muscular trichinosis.

RESUMEN

Trichinella spiralis (T. spiralis) is a prevalent foodborne intestinal parasite in many developing countries. Albendazole (ABZ) is the drug of choice for treating trichinosis despite its several drawbacks as its week effect against encapsulated larvae, low bioavailability, and emerging drug resistance. As a result, new anthelmintic agents are required. This study aims to investigate the in vivo and in vitro effects of Punica granatum peels extract (PGPE) on intestinal and muscle phases of T. spiralis. The adult worms and larvae were isolated and cultured with different concentrations of PGPE ranging from 6.75 to 100 µg/ml and measuring the survival rate was done after 1, 3, 18, 24 and 48 h of incubation, followed by scanning electron microscopic (SEM) examination of isolated parasites. For the in vivo experiment, the infected animals were divided into two main groups: intestinal phase group and muscular phase group, each group was subdivided into; infected not treated, infected treated with PGPE, ABZ and combined PGPE and ABZ (6 mice in each). The drug effect was assessed by adults and larvae load. A significant increase in the percentage of dead adult parasite and muscle larvae cultured with PGPE with severe destruction and deformity of the tegument were observed with SEM. Also, a significant reduction of adult parasite number in the intestine and muscle larva number in the diaphragm of infected treated mice in comparison to the control group. This study proved that PGPE has a potential activity against trichinosis, particularly when combined with ABZ, and this could serve as a new agent in trichinosis therapy.

RESUMEN

Giardia lamblia is one of the most common protozoal parasites in humans, and a major cause of diarrheal illness. Treatment of giardiasis relies on metronidazole (MTZ) and other nitroimidazoles which exhibit some limitations, including variable treatment efficacy and parasite-drug resistance. In this work, we investigated the therapeutic effects of the commercial products of Allium sativum (A. sativum) and Zingiber officinale (Z. officinale), alone and in combination with MTZ, on giardiasis in experimentally infected hamsters. Parasitological assessments: cysts count, cysts viability and trophozoites count, and histopathological assessment were performed. Results revealed that the percentage of reduction in cysts number in the A. sativum, Z. officinale, A. sativum/MTZ, and Z. officinale/MTZ treated groups were of 84.5, 88.9, 82, and 86.1%, respectively, compared to infected non-treated group. While MTZ treated group showed percentage of reduction 79.7%. Regarding the cyst viability, it was reduced by 73.4, 76.9, 64.9, and 70.7%, in the A. sativum, Z. officinale, A. sativum/MTZ, and Z. officinale/MTZ treated groups respectively, compared to 61.9% in the MTZ treated group. For the trophozoites, the percentage of reduction was 64.1, 60.2, 59.4, and 47.3%, respectively, compared to 38.6% in MTZ treated group. The examination of duodenal sections revealed remarkable improvement in the histopathological changes in the A. sativum, Z. officinale, and the MTZ combination groups. In conclusion, A. sativum and Z. officinale preparations showed higher anti-giardial activity compared to MTZ, with higher reduction in Giardia cyst numbers, viability and trophozoite numbers in the experimentally infected hamsters. Further in vivo trials are recommended using A. sativum and Z. officinale preparations in increasing doses to reach a higher cure rate.

RESUMEN

The present study was conducted on 200 male mice for the detection of the effect of Atorvastatin on Cryptosporidium spp. infection versus the commercially used drug Nitazoxanide in experimentally immunosuppressed mice. Atorvastatin was used alone at low dose (20 mg/kg), high dose (40 mg/kg), and combined with Nitazoxanide (1000 mg/kg) with either the low dose or high dose for five consecutive days. Parasitological assessment of the drug effect was done using Modified Z-N staining of stool samples collected from mice. Results revealed a reduction of the number of oocysts shed with percentage of reduction on the 21st day post infection by 53.7%, 67.2%, 70.1% &77.5%, respectively, compared to the infected untreated group. The Nitazoxanide treated group showed 52.7% reduction. In addition, examination of small and large intestinal contents after mice scarification revealed reduced numbers of oocysts by 56.2%-58.8%, 65.1%-65.3%, 70.6%-73.9% and 77.8%-79.9%, respectively, compared to 51.2%-54.1% in Nitazoxanide treated group. The histopathological examination of sections from duodenum, jejunum, ileum, colon, stomach and lungs also revealed a significant improvement of the histopathological changes in Atorvastatin treated groups and more remarkable improvement in the groups treated with combined drugs as compared to infected untreated group. Accordingly, the combination of Atorvastatin and Nitazoxanide showed a synergistic effect through reduction of the number of oocysts shed and improvement of the histopathological changes induced by Cryptosporidium spp. infection in the small intestine, colon, stomach and lungs of infected immunosuppressed mice in comparison to that induced by either Nitazoxanide or Atorvastatin alone.

Asunto(s)

Antiparasitarios/uso terapéutico , Atorvastatina/uso terapéutico , Criptosporidiosis/tratamiento farmacológico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Tiazoles/uso terapéutico , Animales , Antiparasitarios/administración & dosificación , Atorvastatina/administración & dosificación , Colon/parasitología , Colon/patología , Criptosporidiosis/inmunología , Criptosporidiosis/patología , Sinergismo Farmacológico , Duodeno/parasitología , Duodeno/patología , Heces/parasitología , Vesícula Biliar/patología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Íleon/parasitología , Íleon/patología , Terapia de Inmunosupresión , Yeyuno/parasitología , Yeyuno/patología , Pulmón/patología , Masculino , Ratones , Nitrocompuestos , Estómago/patología , Comprimidos , Tiazoles/administración & dosificación

RESUMEN

Increasing prevalence of Cryptosporidium raises the importance to explore different aspects of its infection. In the absence of reproducible in vitro culturing, animal model is the only experimental method to study Cryptosporidium. Our study evaluated Cryptosporidium infection using coproscopy, copro-antigen and copro-DNA for early detection of murine cryptosporidiosis. Hundred and forty albino mice (neonates and adult) were divided into two groups, control group received sterile PBS solution, and infected groups were inoculated with molecularly characterized Cryptosporidium parvum oocysts and further subdivided into three subgroups for infectious dose response detection. Mice fecal samples were collected every 4 h on the first day and then daily and examined for fecal oocysts, copro-antigen and copro-DNA. Four mice from each subgroup were killed at 12, 24 and 48 h post-infection (P-I), and their intestines were examined for cryptosporidial mucosal DNA. Cryptosporidium copro-antigen and copro-DNA were detected 4 and 8 h P-I in infected neonatal and adult mice, respectively, and intestinal mucosal DNA was detected after 12 h in both. Microscopy was able to detect oocysts 48 h P-I. Inoculated C. parvum oocysts were recovered in feces of infected mice without genotypic changes. Neonate mice showed higher susceptibility for cryptosporidial infection than adults without statistical differences for the given infectious doses. Both copro-immunoassay and copro-nPCR assays can early detect Cryptosporidium infection; however, nPCR was able to identify Cryptosporidium species, making nPCR a reliable biomarker for early detection in murine model.